Table 2: Most frequent adverse events that led to discontinuation of nintedanib in patients with autoimmune disease-related ILDs in INBUILD-ON.
Table 2: Most frequent adverse events that led to discontinuation of nintedanib in patients with autoimmune disease-related ILDs in INBUILD-ON.